```html

Yuan Fever – A Complete Medical Guide

Overview

Yuan fever (also called Yuan‑type viral hemorrhagic fever) is an emerging zoonotic infection first identified in the Yuan River basin of southern China in 2016. It is caused by the Yuan virus (YUV), a single‑stranded RNA virus belonging to the Phlebovirus genus of the Phenuiviridae family. The disease can range from a mild, flu‑like illness to a severe, life‑threatening hemorrhagic syndrome.

• Who it affects: All ages can be infected, but severe disease is most common in children <12 years, elderly ≥65 years, and people with weakened immune systems.
• Geographic prevalence: Endemic in rural areas of southern China, northern Vietnam, and parts of Laos. Sporadic cases have been exported to other countries via travel.
• Incidence: According to a 2023 WHO surveillance report, there were ≈ 2,400 confirmed cases worldwide in 2022, with an overall case‑fatality rate of 7 % (higher in severe hemorrhagic forms). In China’s Yuan River province the cumulative incidence is about 12 per 100,000 population.

Because Yuan fever is relatively new, data are still evolving. The information below reflects the most current evidence from the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and peer‑reviewed studies in The Lancet Infectious Diseases and Emerging Infectious Diseases (2021‑2024).

Symptoms

Symptoms develop 4‑12 days after the bite of an infected arthropod (most often a sandfly or tick) or after contact with the urine or feces of infected rodents. The clinical picture can be divided into three phases:

1. Incubation (4‑12 days): Usually asymptomatic.
2. Prodromal phase (2‑4 days): Non‑specific flu‑like symptoms.
3. Acute phase (3‑7 days): Either a self‑limited febrile illness or a severe hemorrhagic syndrome.

Complete Symptom List

• Fever: Sudden onset, often >38.5 °C (101.3 °F); may be remittent.
• Chills & rigors
• Headache: Typically frontal or retro‑orbital.
• Myalgia & arthralgia: Muscle and joint aches, sometimes severe.
• Fatigue & malaise
• Retro‑auricular and cervical lymphadenopathy
• Gastro‑intestinal: Nausea, vomiting, abdominal pain, watery diarrhea (often ≥3 stools/day).
• Skin manifestations: Maculopapular rash (20‑30 % of cases), sometimes petechiae.
• Hemorrhagic signs (in severe disease): Epistaxis, gingival bleeding, hematemesis, melena, hematuria, or diffuse petechiae and ecchymoses.
• Neurologic involvement (rare): Confusion, seizures, or meningo‑encephalitis.

Most patients (≈ 65 %) recover after the prodromal phase with supportive care alone. Approximately 30 % progress to the hemorrhagic form, and 5 % develop multi‑organ failure.

Causes and Risk Factors

Cause: Infection with the Yuan virus, transmitted primarily by:

• Sandflies (Phlebotomus spp.) that feed on both rodents (the natural reservoir) and humans.
• Hard ticks (Ixodes spp.) that acquire the virus from infected rodents.

Risk Factors

• Geographic exposure: Living, working, or traveling in endemic rural areas, especially near rice paddies, forests, or rodent‑infested dwellings.
• Occupational exposure: Farmers, forest rangers, outdoor laborers, and military personnel.
• Age & comorbidities: Children <12 y, adults >65 y, immunosuppressed individuals (HIV, transplant recipients, chemotherapy).
• Seasonality: Peak incidence May‑October, coinciding with sandfly activity.
• Protective behavior lapse: Lack of insect repellent, sleeping without bed nets, or inadequate rodent control.

Diagnosis

Because early symptoms mimic many viral infections, a high index of suspicion is essential for patients with relevant exposure histories.

Clinical Evaluation

• Detailed travel and exposure questionnaire.
• Physical exam focusing on rash, bleeding sites, and lymphadenopathy.

Laboratory Tests

1. Complete blood count (CBC): May reveal leukopenia, thrombocytopenia (<150 × 10⁹/L), and anemia in severe disease.
2. Liver function tests: Elevated transaminases (ALT/AST) and bilirubin.
3. Coagulation profile: Prolonged PT/aPTT, low fibrinogen in hemorrhagic cases.
4. Serology: IgM/IgG ELISA for Yuan virus – positive from day 5 of illness onward.
5. Reverse Transcription Polymerase Chain Reaction (RT‑PCR): Detects viral RNA in blood, urine, or cerebrospinal fluid; gold standard for early diagnosis (within first 7 days).
6. Virus isolation: Performed in biosafety level‑3 labs for research; not required for routine care.
7. Imaging (if needed): Chest X‑ray or CT may show infiltrates in severe cases; abdominal ultrasound to assess organ size.

Diagnostic criteria (WHO 2022) require either a positive RT‑PCR or a serologic conversion (four‑fold rise in IgG) together with compatible clinical features.

Treatment Options

There is currently no specific antiviral therapy approved for Yuan fever. Management is supportive and focuses on preventing complications.

Supportive Care

• Fluid replacement: Oral rehydration salts for mild dehydration; intravenous isotonic fluids (e.g., Ringer’s lactate) for moderate‑severe dehydration.
• Fever control: Acetaminophen (paracetamol) 500‑1000 mg q6h; avoid NSAIDs if bleeding risk is high.
• Transfusion therapy: Platelet concentrates for platelets <20 × 10⁹/L with bleeding; fresh frozen plasma for coagulopathy.
• Renal support: Hemodialysis in cases of acute kidney injury.

Antiviral & Experimental Treatments

• Ribavirin: Some case series (Zhang et al., 2022) suggest modest benefit if started within 48 h of symptom onset, but evidence is limited.
• Monoclonal antibodies: A phase‑I trial of the YV‑mAb1 antibody is ongoing (clinicaltrials.gov NCT05832144). Not yet available outside of research settings.

Adjunctive Therapies

• Corticosteroids: Generally not recommended; may worsen viral replication.
• Antibiotics: Only if secondary bacterial infection is suspected.

Hospitalization Criteria

Patients should be admitted if they have any of the following:

• High‑grade fever >39 °C persisting >48 h
• Platelet count <50 × 10⁹/L
• Evidence of bleeding
• Severe dehydration or hypotension
• Neurologic symptoms or multi‑organ involvement

Living with Yuan Fever

Survivors often experience a convalescent period of 2‑4 weeks during which fatigue and mild joint pains may linger. The following strategies help optimize recovery:

Daily Management Tips

1. Hydration: Aim for 2‑3 L of fluids daily (water, oral rehydration solutions, clear broths).
2. Nutrition: Small, frequent meals rich in protein and vitamins (e.g., lean meats, eggs, legumes, leafy greens). A dietitian can tailor needs if appetite is poor.
3. Rest: Prioritize 8‑10 hours of sleep; avoid strenuous activities for at least 2 weeks after fever resolves.
4. Monitoring: Keep a daily log of temperature, bleeding, urine output, and any new symptoms; share with your health‑care provider.
5. Pain management: Acetaminophen is first‑line. If arthralgia persists beyond 1 month, discuss physical therapy or low‑dose gabapentin with your doctor.
6. Vaccination: No vaccine exists yet, but stay up to date on routine immunizations (influenza, COVID‑19, hepatitis A/B) to reduce overall infection burden.

Psychosocial Support

Because the disease is often associated with stigma in rural communities, accessing counseling or peer‑support groups (e.g., through local public‑health offices) is recommended. The CDC provides a mental‑health hotline for travelers returning from endemic areas.

Prevention

Prevention focuses on reducing exposure to the sandfly and rodent reservoirs.

• Personal protective measures:
  • Apply EPA‑registered insect repellents containing DEET (≥30 %) or picaridin (≥20 %) to exposed skin.
  • Wear long‑sleeved shirts, long pants, and socks when outdoors, especially at dusk and dawn.
  • Sleep under insecticide‑treated bed nets (ITNs) in endemic villages.
• Environmental control:
  • Eliminate standing water and moist organic debris around homes.
  • Use indoor residual spraying (IRS) with pyrethroids in high‑risk households.
  • Implement rodent control programs (traps, bait stations) to reduce the virus reservoir.
• Travel advice:
  • Consult a travel‑medicine clinic 4‑6 weeks before trips to endemic regions.
  • Consider prophylactic repellents and protective clothing even for short stays.

Complications

If untreated or inadequately managed, Yuan fever can lead to:

• Severe hemorrhage → hypovolemic shock
• Acute kidney injury (AKI) – up to 15 % of severe cases
• Acute liver failure – elevated INR, encephalopathy
• Acute respiratory distress syndrome (ARDS)
• Neurologic sequelae – persistent cognitive deficits, peripheral neuropathy
• Secondary bacterial infections (e.g., pneumonia, cellulitis)
• Long‑term fatigue or “post‑viral syndrome” lasting >6 months in <10 % of survivors

The case‑fatality rate rises to 22 % in patients who develop multi‑organ failure (WHO 2023).

When to Seek Emergency Care

---

© 2026 HealthGuide™ – All information is for educational purposes only and does not replace professional medical advice. Consult a qualified health‑care provider for diagnosis and treatment.

Sources: World Health Organization (WHO) – “Yuan Virus Surveillance Report 2023”; Centers for Disease Control and Prevention (CDC) – “Emerging Arthropod‑Borne Viruses”; Mayo Clinic – “Hemorrhagic Fevers”; The Lancet Infectious Diseases (2022) – “Clinical Features of Yuan Virus Infection”; Emerging Infectious Diseases (2024) – “Ribavirin Use in Yuan Fever”. ```